Company intelligence / Profile preview
Essential Pharma
Egham, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Essential Pharma maintains a diverse commercial portfolio (>36 essential medicines) and is developing a late-stage anti-GD2 monoclonal antibody (Hu14.18) for high-risk neuroblastoma. Most products are mature, niche medicines for underserved or rare disease populations; Hu14.18 is reported to be in late-stage clinical development[2][3].
- Therapeutic areas
- OncologyOther
- Modalities
- Monoclonal antibodySmall moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AcedrA BioPharmaceuticals (distribution collaboration in Middle East and North Africa)[4]
Beyond the preview
Go deeper on Essential Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Essential Pharma.